Clincosm LogoSign in Get a demo

Carcinoma, Non-Small-Cell Lung

Showing NaN - NaN of 42
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Worldwide (TAK-788)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Birmingham, Alabama
  • +56 more
Jan 23, 2023

NSCLC Trial in Worldwide (Alectnib, Cisplatin, Vinorelbine)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Chicago, Illinois
  • +140 more
Jan 20, 2023

NSCLC Trial in Worldwide (Sasanlimab Prefilled syringe, Encorafenib, Binimetinib)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Sasanlimab Prefilled syringe
  • +5 more
  • Duarte, California
  • +96 more
Jan 18, 2023

NSCLC Trial in Worldwide (INC280 (capmatinib))

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • INC280 (capmatinib)
  • Long Beach, California
  • +95 more
Dec 29, 2022

NSCLC Trial in Worldwide (Selpercatinib, Placebo)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Santa Monica, California
  • +206 more
Dec 27, 2022

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

Active, not recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +39 more
  • pralsetinib (BLU-667)
  • Phoenix, Arizona
  • +65 more
Nov 10, 2022

Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Worldwide (BLU-945, osimertinib)

Recruiting
  • Lung Neoplasms
  • +23 more
  • La Jolla, California
  • +35 more
Oct 6, 2022

Tumors, NSCLC, Pancreatic Tumors Trial in Worldwide (V941, Pembrolizumab)

Completed
  • Neoplasms
  • +3 more
  • V941
  • Pembrolizumab
  • Gilbert, Arizona
  • +25 more
Sep 5, 2022

NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Pemetrexed)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Phoenix, Arizona
  • +303 more
Aug 17, 2022

NSCLC Trial in Worldwide (Durvalumab + SoC chemo, Placebo + SoC chemo)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Durvalumab + SoC chemotherapy
  • Placebo + SoC chemotherapy
  • Birmingham, Alabama
  • +147 more
Aug 1, 2022

KRAS G12C Mutant Solid Tumors, NSCLC, Carcinoma, Colorectal Trial in Worldwide (JDQ443, TNO155, tislelizumab)

Recruiting
  • KRAS G12C Mutant Solid Tumors
  • +9 more
  • Atlanta, Georgia
  • +31 more
Jul 7, 2022

NSCLC Trial in Worldwide (Lorlatinib, Crizotinib)

Active, not recruiting
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • Altamonte Springs, Florida
  • +164 more
May 27, 2022

NSCLC Trial in Worldwide (FKB238 (bevacizumab), Avastin (bevacizumab), Paclitaxel)

Completed
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • FKB238 (bevacizumab)
  • +3 more
  • Fountain Valley, California
  • +146 more
Feb 25, 2022

NSCLC Trial in Worldwide (Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Bevacizumab, Carboplatin)

Completed
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
  • +3 more
  • Chandler, Arizona
  • +239 more
Aug 26, 2021

NSCLC Trial in Worldwide (LY2875358, Erlotinib)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Herlev, Denmark
  • +41 more
Sep 2, 2021

NSCLC Trial in Worldwide (Avelumab, Docetaxel)

Completed
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • Tuscaloosa, Alabama
  • +259 more
Jul 20, 2020

NSCLC Trial in Worldwide (Afatinib)

Completed
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • Beijing, China
  • +32 more
Jun 27, 2019

NSCLC Trial in Worldwide (afatinib, erlotinib)

Completed
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • Chandler, Arizona
  • +191 more
Feb 8, 2019

NSCLC Trial in Worldwide (AZD9291)

Unknown status
  • Carcinoma, Non-Small-Cell Lung
  • Chai Wan, Hong Kong
  • +7 more
Sep 19, 2018

NSCLC, Brain Tumors Trial in Taipei (Bevacizumab plus erlotinib, Erlotinib)

Unknown status
  • Carcinoma, Non-Small-Cell Lung
  • Brain Neoplasms
  • Taipei, Taiwan
    Department of Oncology, Nationa Taiwan University Hospital
Jul 9, 2018

NSCLC Trial in Worldwide (BI 836845, afatinib)

Completed
  • Carcinoma, Non-Small-Cell Lung
  • Fukuoka, Fukuoka, Japan
  • +9 more
Apr 30, 2018

NSCLC, Adenocarcinoma Trial in Worldwide (Pemetrexed, BIBW 2992, Cisplatin)

Completed
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • Adenocarcinoma
  • Fayetteville, Arkansas
  • +132 more
Mar 9, 2018

NSCLC Trial in Worldwide (Patient Reported Outcomes)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Patient Reported Outcomes
  • Winnipeg, Manitoba, Canada
  • +109 more
Feb 6, 2018

Non-Small-Cell Lung Cancer Stage IIIB, Non-Small-Cell Lung Cancer Stage IV, Non-Small-Cell Lung Cancer Metastatic Trial in

Completed
  • Non-Small-Cell Lung Cancer Stage IIIB
  • +6 more
  • bavituximab
  • +2 more
  • Huntsville, Alabama
  • +160 more
Apr 19, 2017

NSCLC Trial in Worldwide (Investigator´s choice of chemo, BIBW 2992)

Completed
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • Investigator´s choice of chemotherapy
  • BIBW 2992
  • Ciudad Autonoma de Buenos Aires, Argentina
  • +97 more
Feb 15, 2017